Trial Profile
Safety and efficacy of sodium metaarsenite (KML001) as a palliative chemotherapy in patients with advanced billiary tract cancers after gemcitabine based chemotherapy failure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2018
Price :
$35
*
At a glance
- Drugs Sodium metaarsenite (Primary)
- Indications Cholangiocarcinoma; Gallbladder cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Jun 2018 Recruitment was completed in Oct 2014, according to results presented at the Digestive Disease Week 2018.
- 05 Jun 2018 Results presented at the Digestive Disease Week 2018
- 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week